Role of lapatinib in the first-line treatment of patients with metastatic breast cancer

References

• XiaWMullinRJKeithBRAnti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene2002216255626312214266
   PubMed Web of Science ®Google Scholar
• RusnakDWLackeyKAffleckKThe effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivoMol Cancer Ther20011859412467226
   PubMed Web of Science ®Google Scholar
• Lapatinib [package insert].
   Google Scholar
• BenceAKAndersonEBDoukasMAPhase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjectsInvest New Drugs200523394915528979
   PubMed Web of Science ®Google Scholar
• VersolaMBurrisHAJonesSClinical activity of GW572016 in EGF10003 in patients with solid tumorsJ Clin Oncol200414S abstract 3047.
   Google Scholar
• MinamiHNakagawaKKawadaKA phase I study of GW572016 in patients with solid tumorsJ Clin Oncol200414S abstract 3048.
   Google Scholar
• BurrisHAHurwitzHIDeesECPhase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasJ Clin Oncol2005235305531315955900
   PubMed Web of Science ®Google Scholar
• MedinaPJGoodinSLapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinasesClin Ther2008301426144718803986
   PubMed Web of Science ®Google Scholar
• LoRussoPMJonesSFKochKMPhase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancerJ Clin Oncol2008183051305618565892
   PubMed Web of Science ®Google Scholar
• StornioloAMPegramMDOvermoyerBPhase I Dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerJ Clin Oncol2008203317332318490651
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006262733274317192538
   PubMed Web of Science ®Google Scholar
• CiccareseMLorussoVHow should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose?J Clin Oncol2009231431519064955
   PubMed Web of Science ®Google Scholar
• GomezHLDovalDCChavezMAEfficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancerJ Clin Oncol2008182999300518458039
   PubMed Web of Science ®Google Scholar
• KochKMReddyNJCohenRBEffects of food on the relative bioavailability of lapatinib in cancer patientsJ Clin Oncol200981191119619188677
   PubMed Web of Science ®Google Scholar
• BursteinHJStornioloAMFrancoSA phase II study of lapatinib monotherapy in chemotherapy-refractory HER-2 postive and HER2-negative advanced or metastatic breast cancerAnn Oncol200861068107418283035
   PubMed Web of Science ®Google Scholar
• BlackwellKLPegramMDTan-ChiuESingle-agent lapatinib for HER2 overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimensAnn Oncol20092061026103319179558
   PubMed Web of Science ®Google Scholar
• Di LeoAGomezHLAzizZPhase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancerJ Clin Oncol2008345544555218955454
   PubMed Web of Science ®Google Scholar
• JohnstonSPippenPPivotXLapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor–positive metastatic breast cancerJ Clin Oncol2009275538554619786658
   PubMed Web of Science ®Google Scholar
• WolffAHammondMSchwartzJAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol2007111814517159189
   PubMed Web of Science ®Google Scholar
• SimmonsCMillerNGeddieWDoes confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?Ann Oncol200920499504
   Web of Science ®Google Scholar
• MengSTripathyDSheteSHER-2 gene amplification can be acquired as breast cancer progressesProc Natl Acad Sci U S A2004101259393939815194824
   PubMed Web of Science ®Google Scholar
• PestrinMBessiSGalardiFCorrelation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patientsBreast Cancer Res Treat200911852353019597704
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJBlackwellKLBursteinHA randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapyJ Clin Oncol200826Suppl abstract 1015.
   Google Scholar
• KochKMLeeDJonesSPharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patientsEur J Cancer20031SupplS169
   Google Scholar
• BaselgaJCarbonellXCastaneda-SotoNJPhase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly scheduleJ Clin Oncol2005102162217115800309
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol2002371972611821453
   PubMed Web of Science ®Google Scholar
• JonesSFHainsworthJDSpigelDRA phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009)J Clin Oncol20042214S abstract 2083.
   Web of Science ®Google Scholar
• GeeJMHarperMEHutchesonIRThe antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitroEndocrinology20031445105511712960029
   PubMed Web of Science ®Google Scholar
• MackeyJRKaufmanBClemensMTrastuzumab prolongs progression free survival in hormone-dependent and HER2-positive metastatic breast cancerBreast Cancer Res Treat2006100 abstract 3.
   Web of Science ®Google Scholar
• CristofanilliMValeroVMangalikAA phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)J Clin Oncol200826Suppl abstract 1012.
   Google Scholar
• OsborneKNevenPDirixLRandomised phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancerBreast Cancer Res Treat2007106Suppl 1S107
   Google Scholar
• GrilBPalmieriDBronderJLEffect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the BrainJ Natl Cancer Inst2008151092110318664652
   PubMedGoogle Scholar
• LinNUCareyLALiuMCPhase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breastCancer J Clin Oncol20081219931999
   Google Scholar
• LinNUDierasVPaulDEGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)J Clin Oncol20072518S abstract 1012.
   Web of Science ®Google Scholar
• LinNUPaulDDierasVLapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer an updated analysis from EGF105084San Antonio Breast Cancer Symposium2007 abstract 6076.
   Google Scholar
• CrownJPBurrisHABoyleFPooled analysis of diarrhea events in patients with cancer treated with lapatinibBreast Cancer Res Treat2008231732518204897
   PubMed Web of Science ®Google Scholar
• LacoutureMELaabsSMKoehlerMAnalysis of dermatologic events in patients with cancer treated with lapatinibBreast Cancer Res Treat2009348549318600445
   PubMed Web of Science ®Google Scholar
• PerezEByrneJHammondICardiac safety experience in 3127 patients treated with lapatinibAnn Oncol200617Suppl 9ix70 abstract 1420.
   Google Scholar
• RobinsonASEllardSSpeersCClinical and molecular predictors of sustained response to trastuzumab in metastatic breast cancerJ Clin Oncol20052316S abstract 500.
   Web of Science ®Google Scholar
• PegramMCan we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?Clin Breast Cancer20088Suppl 3S121S13018777951
   PubMed Web of Science ®Google Scholar
• XiaWLiuLHHoPTruncated erbB2 receptor (p95erbB2) is regulated by heregulin through heterodimer formation with erbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016Oncogene20042364665314737100
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell2004211712715324695
   PubMed Web of Science ®Google Scholar
• XiaWHusainILiuLLapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancersCancer Res200731170117517283152
   PubMed Web of Science ®Google Scholar
• ArpinoGWiechmannLOsborneCKCrosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistanceEndocr Rev20082921723318216219
   PubMed Web of Science ®Google Scholar
• ChenFLXiaWSpectorNLAcquired resistance to small molecule ErbB2 tyrosine kinase inhibitorsClin Cancer Res2008216730673418980964
   PubMed Web of Science ®Google Scholar
• ZhouXCellaDCameronDLapatinib plus capecitabine versus capecitabine alone for HER2+ (ERbB2+) metastatic breast cancer: quality of life assessmentBreast Cancer Res Treat2009357758919153829
   PubMed Web of Science ®Google Scholar
• CameronDCaseyMPressMA phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Res Treat2008353354318188694
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med200535278679215728811
   PubMed Web of Science ®Google Scholar
• SpectorNLXiaWBurrisHIIIStudy of the biological effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignanciesJ Clin Oncol200511111
   Google Scholar
• GomezHLChavezDCDovalDCInvestigation of tumor biomarkers as response predictors in a monotherapy stucy with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cnacerJ Clin Oncol20072518S abstract 10562.
   Web of Science ®Google Scholar
• FinnRSPressMFDeringJEstrogen receptor, progesterone receptor, human epidermal growth factor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomised trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancerJ Clin Oncol2009243908391519620495
   PubMed Web of Science ®Google Scholar
• CamaraOJörkeCHammerUMonitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatmentJ Cancer Res Clin Oncol2009464364718936973
   PubMed Web of Science ®Google Scholar